FDA Issues Warning for Xeljanz

FDA Issues Warning for Xeljanz

Following The Food and Drug Administration’s (FDA) approval of Xeljanz in 2012, research revealed that the medication might increase certain health concerns. Due to this risk, the FDA requested that Pfizer, the drug’s producer, conduct post-market Phase IV clinical research to evaluate safety.

On September 1, 2021, the FDA issued an important updated warning on Xeljanz saying this drug is linked to an increased risk of heart disease, blood clots, cancer, and death. This warning is among the most serious of the agency’s safety cautions.

When consumers suffer undue harm as a result of taking a defective medication, a skilled lawyer can help them file product liability claims. If enough people are affected by Xeljanz, it may be possible to file a mass tort claim against the drug’s manufacturer.

What is Xeljanz?

Tofacitinib, commonly sold under the brand name Xeljanz, is a medication often used to treat certain forms of arthritis, such as psoriatic arthritis and rheumatoid arthritis. It aids in the reduction of joint discomfort, soreness, and swelling. Xeljanz is also used to treat ulcerative colitis, which is a type of bowel disease. The drug relieves symptoms such as diarrhea, rectal bleeding, and stomach pain.

Xeljanz is available in the form of pills to be taken by mouth, as well as in the form of an oral solution. It’s often given to kids who have a kind of juvenile idiopathic arthritis.

Common Side Effects of Xeljanz

Xeljanz, like most medicines, can produce mild to severe side effects. The potential adverse effects of Xeljanz, as well as measures to mitigate them, should be discussed with your doctor or pharmacist before taking this drug. Below are some common side effects of Xeljanz:

  • Headaches
  • Common cold
  • High blood pressure
  • Rashes
  • Diarrhea

The medicine may increase the risk of blood clots at larger doses, according to preliminary findings. As a result, the FDA issued a warning about Xeljanz in 2019. After the study was completed, it was discovered that there were increased dangers at all doses. The FDA added to the September notice that Xeljanz should only be prescribed to individuals who have not received relief with TNF inhibitors after receiving Enbrel and Humira.

Contact an Attorney Today

If you are currently taking Xeljanz and believe you have suffered harm as a result, one of our attorneys can help you file a claim against the manufacturer. No one should have to suffer undue harm from medications that are meant to facilitate a better quality of life. Contact Jan Dils, Attorneys at Law, today for experienced and compassionate legal representation.

We Won't Take “NO” for an Answer®

To Schedule an Appointment, Call Us Toll Free at 1.877.873.8208 or Email Us for a Prompt Response.

Jan Dils, Attorneys at Law

Jan Dils, Attorneys at Law